Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development. …
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 Australian Biotech
Latest Video
New Stories
-
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News -
Young NZ cancer patients to get funded medicines no matter where they are treated
October 6, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 - - Latest News -
TGA approves Roche's refillable eye implant for wet macular degeneration
October 5, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News